|
US2017216373A1
|
|
Compositions Comprising Probiotic and Prebiotic Components and Mineral Salts, with Lactoferrin
|
|
AU2016203744A1
|
|
Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
|
|
AU2013205352A1
|
|
Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
|
|
WO2008145398A1
|
|
4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
|
|
WO2007099166A1
|
|
Pyrazolo-pyridine derivatives active as kinase inhibitors
|
|
WO2007096334A1
|
|
Pyrrolopyrrolones active as kinase inhibitors
|
|
US2007112020A1
|
|
Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
MY143206A
|
|
1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors
|
|
US2006160874A1
|
|
Heterobicyclic pyrazole derivatives as kinase inhibitors
|
|
US2006106083A1
|
|
Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
US2005043323A1
|
|
Pyrimidylpyrrole derivatives active as kinase inhibitors
|
|
US2005048594A1
|
|
Fluorine NMR spectroscopy for biochemical screening
|
|
US2005032839A1
|
|
Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
BRPI0418427A
|
|
semi-solid matrix pharmaceutical formulations
|
|
EP1534716A1
|
|
Heterobicyclic pyrazole derivatives as kinase inhibitors
|
|
EP1724270A2
|
|
Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
|
